Human Molecular Genetics Advance Access published online on August 8, 2005
Human Molecular Genetics, doi:10.1093/hmg/ddi299
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Medicine and Research Center, Centre Hospitalier de l'Université de Montréal, Hôpital Notre-Dame, suite Y3616-2, 1560 Sherbrooke Street East, Montreal, Quebec
* To whom correspondence should be addressed. The expanded CAG tract diseases are a heterogeneous group of late-onset neurodegenerative disorders characterized by the accumulation of insoluble protein material and premature neuronal cell death. Recent work has provided support for several mechanisms that may account for neurodegeneration, but no unifying mechanism has emerged. We have previously demonstrated in SCA3 that the expanded CAG tract in the MJD-1 transcript is prone to frameshifting that may lead to the production of polyalanine-containing proteins. To further document the occurrence of frameshifting and understand its mechanism and possible role in pathogenesis, a cellular model was established. We show that this phenomenon results from ribosomal slippage to the -1 frame exclusively, that ribosomal frameshifting depends on the presence of long CAG tracts and that polyalanine-frameshifted proteins may enhance polyglutamine associated toxicity, possibly contributing to pathogenesis. Finally, we present evidence that anisomycin, a ribosome-interacting drug that reduces -1 frameshifting, also reduces toxicity, suggesting a new therapeutic avenue for these disorders.
Received June 16, 2005
Revised August 1, 2005
Accepted August 1, 2005
Article
Ribosomal frameshifting on MJD transcripts with long CAG tracts
2 Department of Medicine and Research Center, Centre Hospitalier de l'Université de Montréal, Hôpital Notre-Dame, suite Y3616-2, 1560 Sherbrooke Street East, Montreal, Quebec; Department of Medicine and Research Centre, Centre Hospitalier de l'Université de Montréal, Hôpital Notre-Dame, suite Y3633-1, 1560 Sherbrooke Street East, Montreal, Qc, H2L 4M1, Canada
Guy A. Rouleau, E-mail: Guy.Rouleau{at}umontreal.ca
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
J E Davies and D C Rubinsztein Polyalanine and polyserine frameshift products in Huntington's disease J. Med. Genet., November 1, 2006; 43(11): 893 - 896. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. M. Wills and J. F. Atkins The potential role of ribosomal frameshifting in generating aberrant proteins implicated in neurodegenerative diseases RNA, July 1, 2006; 12(7): 1149 - 1153. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. M. Wills, B. Moore, A. Hammer, R. F. Gesteland, and J. F. Atkins A Functional -1 Ribosomal Frameshift Signal in the Human Paraneoplastic Ma3 Gene J. Biol. Chem., March 17, 2006; 281(11): 7082 - 7088. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Berger, J. E. Davies, S. Luo, M. Y. Pasco, I. Majoul, C. J. O'Kane, and D. C. Rubinsztein Deleterious and protective properties of an aggregate-prone protein with a polyalanine expansion Hum. Mol. Genet., February 1, 2006; 15(3): 453 - 465. [Abstract] [Full Text] [PDF] |
||||



